Nuvation Bio Inc at Citi Global Healthcare Conference Transcript
Good morning. Traver Davis, health care sector specialist at Citi. We're going to kick off day 2 of our Global Healthcare Conference with Nuvation Bio. And with us from the company, we're happy to have David Hung, who's the Founder, President and CEO; as well as Philippe Sauvage, who is the CFO.
And I guess maybe the best way we can do this, I'll give you the floor for a few minutes, if you want to sort of provide a bit of an overview of the company and the exciting things that you're working on, and we'll go into some Q&A.
Thanks so much, Traver. So I think we're entering a very exciting phase for our company. We are now a commercial-stage company. We, as you know, acquired AnHeart Therapeutics a little over a year ago. And with that, we acquired two assets that we felt had great promise for us.
The first one was taletrectinib, which has now been approved as of June 11 this year, under the brand name IBTROZI. And in our first full quarter
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
